# ETV1

Source: https://onco.cc/targets/etv1/  
OnCo record `etv1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ETV1 (ETS translocation variant 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Pancreatic ductal adenocarcinoma, Breast cancer and 4 more.

## Summary

Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3'. Required for olfactory dopaminergic neuron differentiation; may directly activate expression of tyrosine hydroxylase (TH).

CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Trametinib. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes genetic literature 0.61, literature 0.97, genetic association 0.42, somatic mutation 0.83, animal model 0.39). IntOGen calls it a driver in 2 cohorts (1 activating, 1 loss-of-function), covering Invasive Breast Carcinoma, Colon Adenocarcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ETS variant transcription factor 1; ETS translocation variant 1; ER81
- Tags: cancer-genes-wave
- Symbol: ETV1
- Class: transcription
- Biology: Transcriptional activator that binds to DNA sequences containing the consensus pentanucleotide 5'-CGGA[AT]-3'. Required for olfactory dopaminergic neuron differentiation; may directly activate expression of tyrosine hydroxylase (TH). Location: Nucleus (UniProt). Locus 7p21.2 (HGNC).
- Where found: Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903); CIViC evidence names this disease; Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; Breast cancer: IntOGen driver in 1 cohort (BRCA); Colorectal cancer: IntOGen driver in 1 cohort (COAD); Prostate cancer: Open Targets association 0.57 with prostate cancer (MONDO_0008315); Gastric & gastro-oesophageal junction cancer: Open Targets association 0.52 with gastric cancer (MONDO_0001056)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 2 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3490: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3490
- UniProt P50549: https://www.uniprot.org/uniprotkb/P50549/entry
- NCBI Gene 2115: https://www.ncbi.nlm.nih.gov/gene/2115
- Ensembl ENSG00000006468: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000006468

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)

---
JSON: https://onco.cc/api/v1/entities/etv1.json